4-Hydroxybenzoic Acid Restores Endogenous Coenzyme Q10 in COQ2-Deficient Patient

Primary coenzyme Q10 deficiency represents a heterogeneous group of mitochondrial disorders caused by genetic defects in the multi-step biochemical pathway of ubiquinone synthesis [1]. While clinicians typically rely on high-dose oral coenzyme Q10 supplementation, this strategy is frequently hampered by the extreme lipophilicity, poor intestinal absorption, and limited blood-brain barrier penetration of the molecule [2]. These pharmacokinetic hurdles often leave patients with progressive neurological decline or steroid-resistant nephrotic syndrome despite aggressive treatment [3]. Recent research into metabolic bypass strategies has focused on small, water-soluble precursors like 4-hydroxybenzoic acid or vanillic acid that can enter the biosynthetic pathway downstream of specific enzymatic blocks [4, 3]. A recent study evaluates the long-term efficacy and clinical translatability of this substrate enhancement approach, offering a targeted therapeutic pathway for patients with specific genetic variants who fail standard supplementation.